LXRP - Lexaria Bioscience Corp.

Other OTC - Other OTC Delayed Price. Currency in USD

Lexaria Bioscience Corp.

156 Valleyview Road
Kelowna, BC V1X 3M4

SectorConsumer Defensive
IndustryPackaged Foods
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher A. BunkaChairman & CEO120kN/A1962
Mr. John M. DochertyPres & Director117.21kN/A1969
Mr. Allan SpissingerCFO, Corp. Sec. & TreasurerN/AN/A1969
Mr. Alex BlanchardMang. Corp. Communications & Investor RelationsN/AN/AN/A
Dr. Edward ErgenzingerAdvisor & ConsultantN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lexaria Bioscience Corp. focuses on the development of its proprietary nutrient infusion technologies for the production of superfoods, and the production of enhanced food products under the ViPova and Lexaria Energy brands. Its patented nutrient infusion technology, DehydraTECH provides increase in intestinal absorption rates; rapid delivery to the bloodstream; and important taste-masking benefits for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine, and other molecules. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. April 2016. Lexaria Bioscience Corp. was founded in 2004 and is based in Kelowna, Canada.

Corporate Governance

Lexaria Bioscience Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.